Get the Stockscreener App
13.10
0.15%
+0.02
After Hours:
13.10
Takeda Pharmaceutical Co ADR stock is currently priced at $13.10, with a 24-hour trading volume of 1.07M.
It has seen a +0.15% increased in the last 24 hours and a -2.60% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $13.12 pivot point. If it approaches the $13.02 support level, significant changes may occur.
Previous Close:
$13.08
Open:
$13.07
24h Volume:
1.07M
Market Cap:
$41.11B
Revenue:
$29.54B
Net Income/Loss:
$1.01B
P/E Ratio:
29.50
EPS:
0.444
Net Cash Flow:
$1.63B
1W Performance:
-2.75%
1M Performance:
-2.60%
6M Performance:
-6.76%
1Y Performance:
-18.58%
1D Range:
$13.03
$13.12
52W Range:
$12.77
$16.39
Takeda Pharmaceutical Co ADR Stock (TAK) Company Profile
Name
Takeda Pharmaceutical Co ADR
Sector
Phone
81 3 3278 2111
Address
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
Takeda Pharmaceutical Co ADR Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co ADR Stock (TAK) Latest News
What is Takeda Pharmaceutical Co ADR (TAK) Stock Return on Shareholders' Capital? – Sete News - SETE News
SETE News
Takeda Pharmaceutical Co ADR (TAK) shows promising results – US Post News - US Post News
US Post News
10% Owner TAKEDA PHARMACEUTICAL CO LTD sale 3703703 shares of Takeda Pharmaceutical Co ADR [TAK ... - Knox Daily
Knox Daily
Takeda's TAK-861 shows promise in narcolepsy trial By Investing.com - Investing.com
Investing.com
Takeda Pharmaceutical Co ADR (TAK) gets rating Upgrade from BofA Securities – Knox Daily - Knox Daily
Knox Daily
Takeda's rADAMTS13 recommended by EMA for cTTP treatment By Investing.com - Investing.com
Investing.com
Takeda Pharmaceutical Co ADR Stock (TAK) Financials Data
Takeda Pharmaceutical Co ADR (TAK) Revenue 2024
TAK reported a revenue (TTM) of $29.54 billion for the quarter ending March 31, 2024, a -0.79% decline year-over-year.
Takeda Pharmaceutical Co ADR (TAK) Net Income 2024
TAK net income (TTM) was $1.01 billion for the quarter ending March 31, 2024, a -56.60% decrease year-over-year.
Takeda Pharmaceutical Co ADR (TAK) Cash Flow 2024
TAK recorded a free cash flow (TTM) of $1.63 billion for the quarter ending March 31, 2024, a -35.81% decrease year-over-year.
Takeda Pharmaceutical Co ADR (TAK) Earnings per Share 2024
TAK earnings per share (TTM) was $0.3216 for the quarter ending March 31, 2024, a -56.87% decline year-over-year.
Takeda Pharmaceutical Co ADR Stock (TAK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner |
Jan 24 '24 |
Sale |
8.10 |
3,703,703 |
29,999,994 |
3,755,583 |
About Takeda Pharmaceutical Co ADR
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. The company was founded in 1781 and is headquartered in Tokyo, Japan.
1.06%
Cap:
|
Volume (24h):